GUEST COLUMNISTS

• Refresh Your CTA Strategy With Cybersecurity And EHRs In Mind, Part One

  Leibowitz Law experts examine how tech developments affect key CTA provisions and provide practical, technology-inspired updates for your clinical trial agreements. Part one of this two-part series explores cybersecurity and EHR standards. 

• Are Sites Even Using AI?: How Sponsors And CROs Can Support Uptake

  How much are clinical research sites using AI? And how can sponsors and CROs effectively support sites in doing so? Consultant Maria P. Ladd explains.

• 5 Ways AI Is Changing Clinical Research — And How To Embrace It

  Discover how AI is transforming clinical trials, learn real tools already in use, and get practical guidance for clinical professionals — especially CRAs and site teams — looking to upskill in an AI-enhanced environment.

• Going With The Group: Improve Recruitment With Social Psychology And Behavioral Science, Part 2

  In part two of this series, Tatty Scott explores what social psychology tells us about the magnetic pull of groups on individuals’ behavior and how outreach group engagement activities can maximize behavior change to improve recruitment. 

• Improve Patient Recruitment Using Behavioral Science? It's A No-Brainer, Part One

  In part one of this series, recruitment expert Tatty Scott explores the ways behavioral science — such as nudging the brain’s autopilot — can help change patient behavior and sentiment toward trial participation.

• AI In Medical Devices: Meeting The Regulatory Challenge Around The World, Part 2

  This article focuses on the common regulatory threads that connect different regions and the global standards and principles being developed to bring consistency, safety, and trust to AI innovation in medical devices.

• 3 Strategies For A Successful Journey Toward Cell And Gene Therapy Commercialization

  CTMC's Amy Hay provides 3 recommendations for teams developing cell and gene therapies, from clinical research through commercialization.

• How Recursion Is Industrializing Clinical Trials With AI

  Recursion SVP of Clinical Development and Data Science Sid Jain discusses the company's three-point "ClinTech" strategy, focusing on AI-assisted trial design, trial execution, and evidence generation.